B[ackground]{.smallcaps} {#sec1-1}
========================

The use of brain magnetic resonance (MRI) as a diagnostic tool for the prediction of developmental outcome in newborns with hypoxic--ischemic encephalopathy treated with therapeutic hypothermia has obtained a growing importance for the planning of posttreatment intensive care decisions and rehabilitation strategies.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7]\]

The literature is controversial about the optimal timing of neuroimaging for a reliable prediction power.\[[@ref8][@ref9][@ref10][@ref11][@ref12]\] In the pre-hypothermia era, some authors suggested that an early-performed brain MRI (first week after birth) could underestimate the presence and the extension of brain lesions and that the outcome could be better evaluated through scans obtained in later stages (between the second week and the first month after birth).\[[@ref2]\] A different orientation emerges from the few available studies in newborns treated with hypothermia who had received a complete developmental evaluation within the age of 24 months.\[[@ref6][@ref13][@ref14][@ref15]\] Charon *et al.*,\[[@ref7]\] in particular, observed in 29 patients that early-performed brain MRI (between 1 and 6 days after birth) had the same sensitivity for adverse outcomes (100%) and a higher specificity (96.3% vs. 89.3%) than late-performed MRI (between 9 and 21 days after birth). Other authors reported similar data, despite relevant methodological differences in the MRI parameters that were used to define the severity of brain lesions and in the cognitive and motor scales that were used for the evaluation of developmental outcome.\[[@ref13][@ref14][@ref15]\] All these papers were focused on isolated neuroradiological biomarkers (structural, diffusivity, or spectroscopic data were analyzed separately in different samples).\[[@ref6][@ref7][@ref13][@ref14][@ref15]\]

This study aimed to evaluate, in a common sample, the prognostic role of main structural, diffusivity, and spectroscopic indices at brain MRI in the early stages after therapeutic hypothermia for the prediction of developmental outcome.

M[aterials and]{.smallcaps} M[ethods]{.smallcaps} {#sec1-2}
=================================================

All patients with hypoxic--ischemic encephalopathy, who had received therapeutic hypothermia (whole body cooling) in the neonatal age in the Pediatric Intensive Care Unit of the Department of Pediatrics, Child Neurology and Psychiatry at "Sapienza"----University of Rome between January 1, 2011 and December 31, 2015, were enrolled for a retrospective cohort study when both a post-cooling MRI and a complete neurological and neuropsychological follow-up lasting more than two years were available.

In our institutional protocol, the realization of brain MRI was forecasted at the fourth day after birth (after the end of therapeutic hypothermia). MRI was anticipated in newborns with specific indications (i.e., worsening seizures or suspect of cerebral hemorrhage before the fourth day after birth) and postponed in patients whose clinical conditions were not stable enough for a safe transport to our Radiology Section (i.e., patients under nitric oxide).

Brain MRI examinations were performed with 1.5T Siemens AvantoErlangen, Germany, including superconductive magnets (six-channel coil) performing single, multiple, and volumetric acquisitions (sequences GRE, IR, STIR, FLAIR, SSFSE, MTC, and EPI; layer thickness: 0.1--2mm; matrix: 256 × 512). Diffusion-weighted images (DWI) was obtained using a single-shot, echoplanar imaging sequence with diffusion sensitization obtained in 3--12 different directions and *b*-values of 0 and 1.000s/mm^2^. HM spatial resolution was 1.5 × 1.5 × 3mm^3^. Proton magnetic resonance spectroscopic imaging (^1^HMRS) spectra were obtained through the Spectroscopy SV software version 1.0 on Leonardo Workstation (Siemens, Erlangen, Germany).

^1^HMRS and diffusion coefficients were assessed according to postmenstrual ages of the patients.

Two expert pediatric neuroradiologists (CA and CC), who were blinded to the clinical history and to the developmental outcome of the patients (although they were informed about gestational age, it was essential for the evaluation of developmental stages at the scan), separately evaluated all the MRI examinations including visual analysis of severity and distribution of eventual MRI lesions, mean diffusivity of semioval centre and lenticular nuclei, and area under the curve of basal ganglia *N*-acetylaspartate (NAA) at ^1^HMRS. The differences in the evaluations of nonquantitative parameters were then resolved by consensus between the two neuroradiologists.

The severity of MRI lesions was also systematically scored through Bednarek severity scores (a previously published semiquantitative system that considered regional subscores for basal ganglia, white matter, cortex, brainstem, and cerebellum and a global score resulting from the sum of the subscores; see [Table 2](#T2){ref-type="table"}).\[[@ref3]\]

The mean diffusivity of semioval centre and lenticular nuclei through DWI was available for 27/29 patients. ^1^HMRS was performed in 24/29 patients.

All patients underwent periodical neurodevelopmental evaluations and Griffiths Mental Development Scales--third edition (GMDS-III) were used to assess neurocognitive outcome at the age of 24 months. Of the 29 patients, 28 underwent GMDS-III also at the age of 12 months. GMDS-III was administered by an expert infantile neuropsychologist (AR) who was blinded to MRI features of the patients. The developmental outcome was considered unfavorable if GMDS-III global quotient was \<85.

The statistic analysis was performed using Stata Statistical software version 8.1, College Station, USA.

The negative and positive predictive values of early brain MRI were calculated. The Mann--Whitney *U* test was used to evaluate differences in neuromotor and cognitive outcome between patients with no/minimally abnormal brain MRI (Group A----Bednarek severity global score between 48 and 55) and patients with moderate or severe neuroradiological abnormalities (Group B----Bednarek severity global score between 56 and 186).

The correlations between different neuroradiological predictors (Bednarek severity global scores and subscores, mean diffusivity of semioval centre and lenticular nuclei, and area under the curve of basal ganglia NAA at ^1^HMRS) and neuromotor and cognitive outcome (GMDS-III scores at 12 and 24 months) in the whole sample were assessed through Spearman's coefficient. Written informed consent was obtained from the parents of all selected patients and the study was approved by the ethics committee of Sapienza Università di Roma and Umberto I-Policlinico di Roma.

R[esults]{.smallcaps} {#sec1-3}
=====================

In the selected temporal range (January 1, 2011--December 31, 2015), 61 newborns with hypoxic--ischemic encephalopathy underwent therapeutic hypothermia in our institution. Twenty-nine consecutive patients (15 men and 14 women) with all the required criteria were recruited for this study. Two newborns who did not complete therapeutic hypothermia because of complications, three newborns who died before MRI, sixteen newborns who did not reach 24 months of follow-up at the moment of the retrospective analysis, and eleven newborns who were lost in follow-up were excluded from this study.

[Table 1](#T1){ref-type="table"} summarizes auxologic features, Apgar scores, Sarnat stages, arterial blood test values, and amplitude-integrated electroencephalography (aEEG) severity in the neonatal age of all selected patients, whereas neuroradiological and neurocognitive scores are reported, respectively, in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

###### 

Demographic, clinical, arterial blood gas values, and aEEG severity of our cohort

  Patient   Sex   Gestational age (weeks)   Birth weight (g)   Apgar score 1′   Apgar score 5′   Apgar score 10′   Sarnat stage   pH     BE       aEEG (according to Al Naqueeb *et al.*'s classification)
  --------- ----- ------------------------- ------------------ ---------------- ---------------- ----------------- -------------- ------ -------- ----------------------------------------------------------
  1         F     36.5                      2600               4                7                /                 2              7.09   --18.8   Moderately abnormal
  2         M     40                        3110               3                7                /                 2              6.98   --21.9   Moderately abnormal
  3         F     39.7                      3450               3                4                8                 2              7.24   --16.7   Moderately abnormal
  4         M     41.1                      3440               2                7                /                 3              7.12   --20.7   Moderately abnormal
  5         M     39                        3300               3                Intubation       Intubation        3              6.93   --25     Moderately abnormal
  6         F     38                        3000               3                6                7                 2              6.80   --27     Moderately abnormal
  7         M     37.5                      3150               0                3                Intubation        3              6.90   --20     Moderately abnormal
  8         F     41                        2950               0                4                7                 2              6.9    --19     Moderately abnormal
  9         M     39                        4020               5                7                /                 2              7.22   --8.6    Moderately abnormal
  10        F     38                        2700               4                6                Intubation        3              7.06   --15     Severely abnormal
  11        F     37                        3100               5                8                /                 2              7.17   --10.7   Moderately abnormal
  12        M     40                        2960               1                5                8                 2              7.13   --19.9   Moderately abnormal
  13        F     39.8                      2860               2                5                /                 2              6.90   --23     Moderately abnormal
  14        M     37.7                      3770               1                5                8                 2              6.96   --24     Moderately abnormal
  15        M     42.4                      3985               2                5                Intubation        3              6.80   --14.8   Moderately abnormal
  16        F     35.8                      2290               5                7                8                 2              7.10   --13     Moderately abnormal
  17        F     40.3                      3510               3                7                /                 2              7.30   --8.5    Moderately abnormal
  18        F     40.7                      3200               1                4                Intubation        2              7.06   --29     Moderately abnormal
  19        M     34                        2570               0                3                Intubation        3              6.80   --31     Severely abnormal
  20        F     38                        2700               1                4                7                 2              6.86   --22.7   Severely abnormal
  21        F     40                        2900               1                4                Intubation        3              7.04   --17     Severely abnormal
  22        M     40                        2800               4                8                8                 2              7.30   --6.7    Moderately abnormal
  23        M     40                        2900               2                5                Intubation        2              7.29   --13     Severely abnormal
  24        F     38.2                      2480               3                Intubation       Intubation        3              7.23   --17.5   Severely abnormal
  25        M     40                        3820               1                4                6                 2              7.20   --14     Moderately abnormal
  26        M     40.5                      2670               4                8                8                 2              7.28   --12     Moderately abnormal
  27        F     40                        3200               1                5                7                 2              7.24   --9      Moderately abnormal
  28        M     39                        2950               5                8                8                 2              7.10   --22.1   Moderately abnormal
  29        M     39                        3950               6                8                10                2              7.14   --16.7   Moderately abnormal

aEEG = amplitude-integrated electroencephalography, BE = base excess

###### 

Neuroradiological data of our cohort including age at MRI, visual evaluation, Bednarek severity scores, area under NAA curve in basal ganglia, and mean diffusivity in semioval centre and lenticular nuclei

  Patient   Age at the MRI (days)   Type of brain lesions at visual evaluation                                                                                                                                      Bednarek severity scores\[[@ref3]\]   ^1^HMRS   DWI   Group                                             
  --------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- --------- ----- ------- ---- ---- ---------- ------ ------ ------ ---
  1         7                       Left peritrigonal hemorrhage and bilateral T-2 hyperintensity in both thalami                                                                                                   80                                    42        20    6       6    6    NA         NA     1.9    1.06   B
  2         4                       Pale bilateral periventricular T2-hyperintensity                                                                                                                                50                                    24        8     6       6    6    NA         82.8   1.7    1.1    A
  3         1                       Pale left lenticular T2-hyperintensity                                                                                                                                          50                                    26        6     6       6    6    85.4       93.3   1.6    1.1    A
  4         5                       None                                                                                                                                                                            48                                    24        6     6       6    6    NA         82     1.4    1.1    A
  5         3                       None                                                                                                                                                                            48                                    24        6     6       6    6    NA         88.8   1.6    1.1    A
  6         4                       Bilateral subcortical ischemic lesion involving parietal regions and pons                                                                                                       58                                    24        12    6       6    10   140        126    1.1    0.8    B
  7         4                       IVH grade I, pale bilateral periventricular and cerebellar T2-hyperintensity                                                                                                    58                                    24        10    6       12   6    NA         94.3   1.7    1.2    B
  8         5                       None                                                                                                                                                                            48                                    24        6     6       6    6    101        111    1.7    1      A
  9         4                       None                                                                                                                                                                            48                                    24        6     6       6    6    NA         NA     NA     NA     A
  10        4                       None                                                                                                                                                                            48                                    24        6     6       6    6    111        97.1   1.8    1      A
  11        5                       Bilateral hemispheric white matter and basal ganglia T2-hyperintensity                                                                                                          72                                    34        20    6       6    6    66.6       84.9   1.6    1.1    B
  12        5                       None                                                                                                                                                                            48                                    24        6     6       6    6    NA         30.4   1.6    1.13   A
  13        4                       None                                                                                                                                                                            48                                    24        6     6       6    6    NA         84.4   1.7    1      A
  14        4                       None                                                                                                                                                                            48                                    24        6     6       6    6    124        136    1.6    1      A
  15        5                       Pale periventricular T2-hyperintensity                                                                                                                                          49                                    24        7     6       6    6    148        89.8   1.6    1      A
  16        5                       Ischemic lesions in the right semioval centre and in periventricular zones                                                                                                      63                                    24        19    6       8    6    79.6       66     2      1.4    B
  17        4                       Pale T-2 hyperintensity involving both thalami and periventricular zones                                                                                                        62                                    26        18    6       6    6    80         65     1.8    1.08   B
  18        4                       None                                                                                                                                                                            48                                    24        6     6       6    6    8.391 pt   70     1.4    1.08   A
  19        5                       Diffuse T2-hyperintensity involving bilateral hemispheric white matter, cerebellum, and basal ganglia. IVH grade II                                                             128                                   72        24    14      12   6    NA         24.9   1.7    1.2    B
  20        3                       T1-hypointensity involving thalami, posterior part of internal capsula, cerebral peduncles, temporal lobes, diencephalic region, optical radiations and periventricular areas   88                                    62        8     6       6    6    NA         72.4   1.66   0.9    B
  21        4                       Bilateral T2 hyperintensity in lenticular nuclei and periventricular areas                                                                                                      62                                    36        8     6       6    6    NA         77.7   1.8    1.2    B
  22        5                       Pale T2-hyperintensity involving periventricular areas and lenticular nuclei                                                                                                    50                                    24        8     6       6    6    NA         NA     1.6    1.1    A
  23        20                      None                                                                                                                                                                            48                                    24        6     6       6    6    NA         NA     0.8    0.7    A
  24        6                       None                                                                                                                                                                            48                                    24        6     6       6    6    NA         50.9   1.6    1.1    A
  25        5                       Ischemic lesions involving lenticular nuclei and pons                                                                                                                           59                                    32        6     6       6    9    NA         77.3   1.4    1.2    B
  26        7                       Bilateral diffusion restriction in both thalami and in periventricular areas                                                                                                    64                                    24        22    6       6    6    NA         NA     NA     NA     B
  27        14                      None                                                                                                                                                                            48                                    24        6     6       6    6    101        111    1.7    1      A
  28        11                      T2-hyperintensity of both thalami                                                                                                                                               64                                    40        6     6       6    6    80.4       92.1   1.8    1.03   B
  29        10                      None                                                                                                                                                                            48                                    24        6     6       6    6    NA         86.8   1.4    1.3    A

^1^HMRS = proton magnetic resonance spectroscopy, NAA = *N*-acetylaspartate, AUC = area under the curve, R = range, IVH = intraventricular hemorrhage, DWI = diffusion-weighted images, NA = NA not available

Group A included patients with no/minimally abnormal brain MRI (Bednarek severity global score between 48 and 55), whereas Group B included newborns with moderate or severe neuroradiological abnormalities (Bednarek severity global score between 56 and 186)

###### 

GMDS-III scores and equivalent ages at 12 and 24 months in our cohort

  Patient   GMDS-III scores at 12 months   GMDS-III scores at 24 months                                                                                                                            
  --------- ------------------------------ ------------------------------ ------------ ------------ ------------ ---------------- ------------ ------------ ------------ ------------ ------------ ----------------
  1         100 (12 m)                     92 (11 m)                      92 (11 m)    92 (11 m)    92 (11 m)    94 (11 m)        100 (24 m)   92 (22 m)    100 (24 m)   96 (23 m)    92 (22 m)    **96 (23 m)**
  2         100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  3         100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  4         100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   96 (23 m)    87 (21 m)    100 (24 m)   98 (23 m)    **96 (23 m)**
  5         100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   96 (23 m)    87 (21 m)    100 (24 m)   98 (23 m)    **96 (23 m)**
  6         100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  7         100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  8         100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **102 (12 m)**   100 (24 m)   92 (22 m)    92 (22 m)    100 (24 m)   97 (23 m)    **96 (23 m)**
  9         100 (12 m)                     100 (12 m)                     100 (12 m)   92 (11 m)    96 (11 m)    **98 (11 m)**    100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  10        100 (12 m)                     92 (11 m)                      92 (11 m)    100 (12 m)   94 (11 m)    **95 (11 m)**    100 (24 m)   92 (22 m)    92 (22 m)    100 (24 m)   92 (22 m)    **95 (23 m)**
  11        75 (9 m)                       83 (10 m)                      75 (9 m)     83 (10 m)    80 (10 m)    **80 (10 m)**    46 (11 m)    56(13m)      37 (9 m)     56 (13m)     56 (13m)     **49 (11 m)**
  12        100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  13        100 (12 m)                     100 (12 m)                     100 (12 m)   100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  14        NP                             NP                             NP           NP           NP           **NP**           100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  15        100 (12 m)                     92 (11 m)                      92 (11 m)    100 (12 m)   100 (12 m)   **97 (11 m)**    100 (24 m)   96 (23 m)    83 (20 m)    100 (24 m)   97 (23 m)    **95 (23 m)**
  16        100 (12 m)                     83 (10 m)                      92 (11 m)    92 (11 m)    92 (11 m)    **92 (11 m)**    100 (24 m)   92 (22 m)    100 (24 m)   100 (24 m)   97 (23 m)    **100 (24 m)**
  17        100 (12 m)                     75 (9 m)                       83 (10 m)    83 (10 m)    83 (10 m)    **85 (10 m)**    87 (21 m)    75 (18m)     62 (15 m)    71 (17m)     75 (18m)     **74 (18 m)**
  18        92 (11 m)                      92 (11 m)                      92 (11 m)    92 (11 m)    92 (11 m)    **92 (11 m)**    100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   91 (22 m)    **100 (24 m)**
  19        100 (12 m)                     92 (11 m)                      83 (10 m)    100 (12 m)   100 (12 m)   **95 (11 m)**    100 (24 m)   87 (21 m)    79 (19 m)    100 (24 m)   96 (23 m)    **92 (22 m)**
  20        16 (2 m)                       16 (2 m)                       16 (2 m)     16 (2 m)     16 (2 m)     **16 (2 m)**     12 (3 m)     8 (2 m)      8 (2 m)      8 (2 m)      8 (2 m)      **9 (2 m)**
  21        75 (9 m)                       75 (9 m)                       67 (8 m)     75 (9 m)     75 (9 m)     **73 (9 m)**     54 (13m)     75 (18m)     50 (12 m)    75 (18m)     79 (19 m)    **67 (16 m)**
  22        83 (10 m)                      83 (10 m)                      83 (10 m)    83 (10 m)    83 (10 m)    **100 (12 m)**   90 (21 m)    87 (21 m)    90 (21 m)    90 (21 m)    91 (22 m)    **91 (22 m)**
  23        100 (12 m)                     92 (11 m)                      83 (10 m)    92 (11 m)    94 (11 m)    **92 (11 m)**    100 (24 m)   96 (23 m)    92 (22 m)    94 (23 m)    94 (23 m)    **95 (23 m)**
  24        92 (11 m)                      92 (11 m)                      83 (10 m)    94 (11 m)    94 (11 m)    **91 (11 m)**    96 (23 m)    96 (23 m)    92 (22 m)    96 (23 m)    96 (23 m)    **95 (23 m)**
  25        42 (5m)                        58 (7m)                        58 (7m)      50 (6 m)     50 (6 m)     **52 (6 m)**     41 (10 m)    66 (16 m)    75 (18 m)    79 (19 m)    75 (18 m)    **68 (16 m)**
  26        100 (12 m)                     100 (12 m)                     83 (10 m)    100 (12 m)   100 (12 m)   **99 (12 m)**    100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   100 (24 m)   **100 (24 m)**
  27        100 (12 m)                     100 (12 m)                     83 (10 m)    100 (12 m)   100 (12 m)   **99 (11 m)**    100(24 m)    96 (23 m)    80 (19 m)    100 (24 m)   100 (24 m)   **95 (23 m)**
  28        100 (12 m)                     100 (12 m)                     83 (10 m)    100 (12 m)   100 (12 m)   **97 (11 m)**    100 (24 m)   79 (19 m)    62 (12 m)    79 (19 m)    79 (19 m)    **80 (19 m)**
  29        100 (12 m)                     100 (12 m)                     92 (11 m)    100 (12 m)   100 (12 m)   **100 (12 m)**   100 (24 m)   96 (23 m)    87 (21 m)    96 (23 m)    92 (22 m)    **94 (23 m)**

NP = not performed, m = months

The mean age at MRI was 5.7 ± 3.7 days after birth (range 1--20 days). At visual evaluation of MRI, brain lesions were prominently ischemic \[[Table 2](#T2){ref-type="table"}\] with the involvement of different sites mainly including basal ganglia (nine patients) and periventricular area (nine patients). Intraventricular hemorrhages were seen in two patients (Patients 7 and 19) \[[Table 2](#T2){ref-type="table"}\]. No brain lesions were seen in 13 patients (Patients 4, 5, 8, 9, 10, 12, 13, 14, 18, 23, 24, 27, and 29) \[[Table 2](#T2){ref-type="table"}\]. Group A included 17/29 subjects (58.6%: 10 men and 7 women) whereas Group B included 12/29 subjects (41.4%: 5 men and 7 women).

The correlation between Bednarek severity global score and GMDS-III scores showed that early post-cooling brain MRI had a negative predictive value of 93.75% at 12 months and 100% at 24 months and a positive predictive value of 36.36% at 12 months and 50% at 24 months for an unfavorable developmental outcome.

The Mann--Whitney *U* test showed a significantly higher mean gestational age in Group A than in Group B and a higher birthweight (even if not statistically significant), whereas no significant differences were found in terms of Apgar score \[[Table 4](#T4){ref-type="table"}\]. Children belonging to Group A had higher mean values of global quotient, subitem scores, and equivalent ages at GMDS-III than children belonging to Group B \[[Table 4](#T4){ref-type="table"}\]. Patients of Group A had also higher mean area under NAA curve in basal ganglia than members of Group B (106.22 ± 24.70 vs. 89.32 ± 28.92 in the right side and 86.60 ± 25.35 in the left side) with no relevant differences in mean diffusivity in the analyzed structures.

###### 

Comparison between patients with normal/minimally abnormal brain MRI (Group A) and patients with moderate-to-severe neuroradiological abnormalities (Group B) through Mann--Whitney *U* test

  General features                     Group A                                Group B                                *P* value
  ------------------------------------ -------------------------------------- -------------------------------------- ---------------
  Number of patients                   17                                     12                                     NA
   Sex Males                           10                                     5                                      0.362\*
   Females                             7                                      7                                      
  Mean gestational age                 39.74 ± 1.19 w                         38.05 ± 2.01 w                         0.0339
  (median gestational age)             (*M* = 40; Min = 37,7; Max = 42,4)     (*M* = 38; Min = 34; Max = 40,5)       
  Mean birthweight                     3239.70 ± 470.47 g                     2938.33 ± 424.23 g                     0.0881
  (median birthweight)                 (*M* = 3200; Min = 2480; Max = 4020)   (*M* = 2925; Min = 2290; Max = 3820)   
  Mean Apgar score                     2.52 ± 1.58                            2.66 ± 1.96                            0.8396
  (median Apgar score)                 (*M* = 2; Min = 0; Max = 6)            (*M* = 3; Min = 0; Max = 5)            
  1′                                                                                                                 
  Mean Apgar score                     5.66 ± 1.39                            5.75 ± 2.00                            0.9801
  (median Apgar score)                 (*M* = 5; Min = 4; Max = 8)            (*M* = 6,5; Min = 3; Max = 8)          
  5′                                                                                                                 
                                                                                                                     
  **GMDS-III at 12 months**            **Group A**                            **Group B**                            ***P* value**
  **mean scores at 12 months**         **mean scores at 12 months**                                                  
  **(median sores at 12 months)**      **(median scores at 12 months)**                                              
                                                                                                                     
  Locomotor development score          97.62 ± 4.45                           82.54 ± 28.84                          0.2708
  (*M* = 100; Min = 86; Max = 100)     (*M* = 100; Min = 16; Max = 100)                                              
  Hand and eye coordination score      95.93 ± 5.22                           79.45 ± 24.76                          0.0196
  (*M* = 100; Min = 83; Max = 100)     (*M* = 83; Min = 16; Max = 100)                                               
  Hearing and speech score             93.25 ± 7.05                           75.63 ± 22.99                          0.0053
  (*M* = 92; Min = 83; Max = 100)      (*M* = 83; Min = 16; Max = 100)                                               
  Personal--social development score   97.06 ± 5.02                           81 ± 26.29                             0.0294
  (*M* = 100; Min = 83; Max = 100)     (*M* = 92; Min = 16; Max = 100)                                               
  Performance tests score              96.75 ± 5.03                           81 ± 26.33                             0.0435
  (*M* = 100; Min = 83; Max = 100)     (*M* = 92; Min = 16; Max = 100)                                               
  Global quotient                      96.31 ± 4.86                           80.27 ± 25.62                          0.0199
  (*M* = 98.5; Min = 83; Max = 100)    (*M* = 92; Min = 16; Max = 100)                                               
                                                                                                                     
  **GMDS-III at 24 months**            **Group A**                            **Group B**                            ***P* value**
  **mean scores at 24 months**         **mean scores at 24 months**                                                  
  **(median sores at 24 months)**      **(median sores at 24 months)**                                               
                                                                                                                     
  Locomotor development score          99.76 ± 0.97                           78.33 ± 31.32                          0.0147
  (*M* = 100; Min = 96; Max = 100)     (*M* = 100; Min = 12; Max = 100)                                              
  Hand and eye coordination score      97.05 ± 3.32                           77.5 ± 26.05                           0.0069
  (*M* = 96; Min = 90; Max = 100)      (*M* = 83; Min = 8; Max = 100)                                                
  Hearing and speech score             93.64 ± 6.91                           72.75 ± 30.11                          0.0853
  (*M* = 92; Min = 80; Max = 100)      (*M* = 77; Min = 8; Max = 100)                                                
  Personal--social development score   98.58 ± 2.89                           80.33 ± 27.173                         0.0182
  (*M* = 100; Min = 90; Max = 100)     (*M* = 87.5; Min = 8; Max = 100)                                              
  Performance tests score              96.88 ± 3.68                           79.75 ± 26.45                          0.0303
  (*M* = 98; Min = 90; Max = 100)      (*M* = 85.5; Min = 8; Max = 100)                                              
  Global quotient                      97.17 ± 2.94                           77.91 ± 27.46                          0.0589
  (*M* = 96; Min = 91; Max = 100)      (*M* = 86; Min = 9; Max = 100)                                                

NA = not applicable, w = weeks, g = grams, M = median, Min = minimum, Max = maximum, GMDS-III = Griffiths Mental Development Scales-III rd edition

\*Chi-squared test

The analysis of the whole sample through Spearman's coefficient showed a weak correlation between all Bednarek severity scores and GMDS-III scores both at the age of 12 and 24 months \[[Table 5](#T5){ref-type="table"}\]. Among severity regional subscores, basal ganglia score had the strongest correlation with both GMDS-III global quotient and subitem scores \[[Table 5](#T5){ref-type="table"}\]. A strong correlation was also recorded between area under NAA curve in basal ganglia and both GMDS-III global quotient and subitem scores with higher mean Spearman's coefficients at the age of 12 months than at the age of 24 months \[[Table 5](#T5){ref-type="table"}\]. None of the patients had detectable lactate peaks at ^1^HMRS. No significant correlations were found between mean diffusivity data and neuropsychological indices \[[Table 5](#T5){ref-type="table"}\].

###### 

Correlations between neuroradiological predictors (Bednarek severity scores, area under NAA curve in basal ganglia and mean diffusivity in semioval centre and lenticular nuclei) and GMDS-III scores in our cohort at 12 and 24 months through Spearman's coefficient

  GMDS-III at 12 months                Basal ganglia score       White matter score       Cortex score       Cerebellum score       Brainstem score       Global score       NAA--AUC right basal       NAA--AUC left basal ganglia       Semioval centre mean diffusivity       Lenticular nuclei mean diffusivity
  ------------------------------------ ------------------------- ------------------------ ------------------ ---------------------- --------------------- ------------------ -------------------------- --------------------------------- -------------------------------------- ----------------------------------------
  Locomotor development score          *R* = --0.3207            *R* = --0.0487           *R* = 0.1249       *R* = 0.2248           *R* = --0.3746        *R* = --0.2048     *R* = 0.7028               *R* = 0.2936                      *R* = 0.2896                           *R* = --0.1251
  *P* = 0.1029                         *P* = 0.8093              *P* = 0.5349             *P* = 0.2597       *P* = 0.0542           *P* = 0.3054          *P* = 0.0234       *P* = 0.1847               *P* = 0.1602                      *P* = 0.5513                           
  Hand and eye coordination score      *R* = --0.4624            *R* = --0.3764           *R* = --0.0669     *R* = --0.0357         *R* = --0.3211        *R* = --0.4459     *R* = 0.4782               *R* = 0.4711                      *R* = --0.0635                         *R* = --0.0649
  *P* = 0.0152                         *P* = 0.0530              *P* = 0.7403             *P* = 0.8598       *P* = 0.1025           *P* = 0.0197          *P* = 0.1621       *P* = 0.0269               *P* = 0.7629                      *P* = 0.7580                           
  Hearing and speech score             *R* = --0.5511            *R* = --0.3153           *R* = --0.1435     *R* = 0.0939           *R* = --0.3130        *R* = --0.5144     *R* = 0.4112               *R* = 0.2853                      *R* = 0.0106                           *R* = 0.0453
  *P* = 0.0029                         *P* = 0.1091              *P* = 0.4753             *P* = 0.6413       *P* = 0.1119           *P* = 0.0060          *P* = 0.2377       *P* = 0.1981               *P* = 0.9600                      *P* = 0.8297                           
  Personal--social development score   *R* = --0.4246            *R* = --0.2724           *R* = 0.1667       *R* = 0.1302           *R* = --0.3333        *R* = --0.3751     *R* = 0.8282               *R* = 0.5003                      *R* = 0.0289                           *R* = --0.0430
  *P* = 0.0273                         *P* = 0.1693              *P* = 0.4061             *P* = 0.5173       *P* = 0.0893           *P* = 0.0539          *P* = 0.0031       *P* = 0.0177               *P* = 0.8910                      *P* = 0.8383                           
  Performance tests score              *R* = --0.3957            *R* = --0.2478           *R* = 0.1717       *R* = 0.1330           *R* = --0.3170        *R* = --0.3418     *R* = 0.7268               *R* = 0.4232                      *R* = 0.0039                           *R* = --0.0892
  *P* = 0.0411                         *P* = 0.2127              *P* = 0.3918             *P* = 0.5085       *P* = 0.1071           *P* = 0.0810          *P* = 0.0173       *P* = 0.0497               *P* = 0.9852                      *P* = 0.6716                           
  General quotient                     *R* = --0.4700            *R* = --0.2951           *R* = --0.0128     *R* = 0.0721           *R* = --0.3065        *R* = --0.4230     *R* = 0.6718               *R* = 0.4295                      *R* = 0.0002                           *R* = 0.0044
  *P* = 0.0134                         *P* = 0.1351              *P* = 0.9496             *P* = 0.7209       *P* = 0.1200           *P* = 0.0279          *P* = 0.0334       *P* = 0.0461               *P* = 0.9992                      *P* = 0.9834                           
                                                                                                                                                                                                                                                                                 
  **GMDS-III at 24 months**            **Basal ganglia score**   **White matter score**   **Cortex score**   **Cerebellum score**   **Brainstem score**   **Global score**   **NAA--AUC right basal**   **NAA--AUC left basal ganglia**   **Semioval centre mean diffusivity**   **Lenticular nuclei mean diffusivity**
                                                                                                                                                                                                                                                                                 
  Locomotor development score          *R* = --0.5553            *R* = --0.1886           *R* = 0.0957       *R* = 0.1718           *R* = --0.2169        *R* = --0.3981     *R* = 0.5331               *R* = 0.4047                      *R* = --0.0201                         *R* = --0.1252
  *P* = 0.0018                         *P* = 0.3271              *P* = 0.6215             *P* = 0.3729       *P* = 0.2585           *P* = 0.0325          *P* = 0.0743       *P* = 0.0498               *P* = 0.9206                      *P* = 0.5336                           
  Hand and eye coordination score      *R* = --0.6843            *R* = --0.2975           *R* = --0.1869     *R* = --0.0441         *R* = --0.0383        *R* = --0.5506     *R* = 0.4696               *R* = 0.2979                      *R* = --0.3328                         *R* = --0.0958
  *P* = 0.0000                         *P* = 0.1171              *P* = 0.3316             *P* = 0.8203       *P* = 0.8438           *P* = 0.0020          *P* = 0.1235       *P* = 0.1575               *P* = 0.0898                      *P* = 0.6345                           
  Hearing and speech score             *R* = --0.5763            *R* = --0.1123           *R* = --0.1898     *R* = 0.1057           *R* = --0.0071        *R* = --0.3615     *R* = 0.2461               *R* = 0.2156                      *R* = --0.0847                         *R* = --0.0101
  *P* = 0.0011                         *P* = 0.5619              *P* = 0.3241             *P* = 0.5852       *P* = 0.9710           *P* = 0.0540          *P* = 0.4407       *P* = 0.3116               *P* = 0.6746                      *P* = 0.9600                           
  Personal--social development score   *R* = --0.6191            *R* = --0.1867           *R* = 0.1425       *R* = 0.2558           *R* = --0.0649        *R* = --0.4546     *R* = 0.5609               *R* = 0.3199                      *R* = --0.0410                         *R* = --0.0352
  *P* = 0.0003                         *P* = 0.3322              *P* = 0.4609             *P* = 0.1805       *P* = 0.7379           *P* = 0.0132          *P* = 0.0578       *P* = 0.1275               *P* = 0.8389                      *P* = 0.8616                           
  Performance tests score              *R* = --0.6107            *R* = --0.1826           *R* = --0.0349     *R* = 0.1209           *R* = --0.0300        *R* = --0.4346     *R* = 0.6447               *R* = 0.4059                      *R* = --0.0990                         *R* = --0.0601
  *P* = 0.0004                         *P* = 0.3430              *P* = 0.8574             *P* = 0.5320       *P* = 0.8772           *P* = 0.0185          *P* = 0.0236       *P* = 0.0491               *P* = 0.6232                      *P* = 0.7657                           
  General quotient                     *R* = --0.6258            *R* = --0.1556           *R* = --0.1645     *R* = 0.1331           *R* = --0.0309        *R* = --0.4056     *R* = 0.2342               *R* = 0.2498                      *R* = --0.0948                         *R* = --0.0319
  *P* = 0.0003                         *P* = 0.4203              *P* = 0.3938             *P* = 0.4912       *P* = 0.8735           *P* = 0.0290          *P* = 0.4638       *P* = 0.2391               *P* = 0.6381                      *P =* 0.8743                           

D[iscussion]{.smallcaps} {#sec1-4}
========================

The results of our study highlight the following \[[Tables 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}\]: (a) a normal early post-cooling brain MRI is strongly associated with a favorable cognitive and motor outcome (high negative predictive value for psychomotor delay both at the age of 12 and 24 months); (b) the presence of abnormalities at early post-cooling brain MRI is not necessarily related with an unfavorable outcome; and (c) structural and spectroscopic abnormalities in basal ganglia at early post-cooling brain MRI can be considered as a reliable predictor for an adverse motor and cognitive outcome, whereas structural lesions and diffusion abnormalities involving other cerebral sites (including cortex, cerebellum, brainstem, or white matter) often fail to predict developmental delay.

The high negative predictive value for a favorable developmental outcome of early post-cooling brain MRI, in our sample, agreed with similar previously published data by Charon *et al.*\[[@ref6]\] and Kasdorf *et al*.\[[@ref14]\] As additional points of strength, our study includes a more homogenous and adequate measurement of cognitive outcome for the considered age-range (Charon *et al.* used Brunet Lezine Revised Scale up to 30 months and, for children between 30 and 41 months, neurological examination only) and a large number of tested neuroradiological parameters (both the aforementioned studies did not include spectroscopic data).\[[@ref6][@ref14]\] A lower negative predictive value (74%) was reported in older newborns (mean age at MRI of 8 days) by Rollins *et al.*\[[@ref10]\] and Chalak *et al*.\[[@ref11]\] These authors observed a significant quote of cooled patients with normal or minimally altered MRI who developed moderate (20%--70% of patients) or severe developmental delay (6% of patients).\[[@ref10][@ref11]\] These conflicting results suggest caution in the parental counseling after a normal early post-cooling MRI and impose periodical developmental evaluations beyond the first two years after birth.\[[@ref6][@ref7][@ref9][@ref10][@ref11][@ref14][@ref15]\] This approach could be useful for the choice of the best timing for performing subsequent MRI in patients with a normal early MRI and without progress in developmental milestones despite an optimal cooling and rehabilitative management.\[[@ref11]\]

In our sample, the presence of moderate or severe MRI abnormalities after cooling (patients belonging to Group B) scarcely correlated with an unfavorable developmental outcome. The positive predictive values of MRI at 12 and 24 months were lower than in previous studies.\[[@ref9][@ref10][@ref11][@ref13]\] Single case inspection confirmed a remarkable interindividual variability in neuromotor and cognitive outcome independently from neuroradiological pattern. For example, Patient 19 \[see [Figure 1](#F1){ref-type="fig"} in Supplementary Material for MRIs\] had the highest Bednarek severity global score of our cohort (128/186), but he indicated only a mild delay at GMDS-III (at 24 months general quotient was 92 with an equivalent age of 22 months). These results can be interpreted through the frequent transient nature of several signal MRI abnormalities in the early post-cooling stages (especially the ones following less severe ischemic insults that are more responsive to therapeutic hypothermia). Another possible explanation is given by the assumption that prognostic meaning of MRI abnormalities varies according to the site and the extension of the lesions regardless of hypothermia as it was reported by Cheong *et al.*\[[@ref9]\] and Rutherford *et al.*\[[@ref13]\] in representative subgroups from two large controlled randomized trials.

![(A) T1-weighted axial image showing hyperintensity on basal ganglia and thalami. (B--C) T2-weighted axial images showing diffuse hyperintensity involving bilateral hemispheric white matter and basal ganglia. IVH grade II is seen on the right frontal horn of lateral ventricle. (D) Spectroscopy sequence obtained on the left basal ganglia](JPN-14-191-g001){#F1}

Our study confirmed, according to the data of the literature the relevant role of basal ganglia involvement in ischemic perinatal damages as a reliable predictor of unfavorable outcome after cooling.\[[@ref13][@ref14][@ref15]\] These data also showed that the lack of neuroradiological abnormalities in basal ganglia can be considered as a good marker of the neuroprotective action of therapeutic hypothermia against reperfusion damages.\[[@ref13][@ref14][@ref15][@ref16]\] Lesions involving basal ganglia in hypoxic--ischemic encephalopathy results in an impaired regulation of motor control, acquisition of language abilities, reasoning, and reward-based learning during the development.\[[@ref17]\] Kasdorf *et al.*\[[@ref14]\] reported that newborns with basal ganglia lesions after therapeutic hypothermia presented with a more frequent necessity of neonatal cardiopulmonary resuscitation, a more persistent severe acidosis, more severe electroencephalographic abnormalities, a higher quote of encephalopathic features, and a more frequent abnormal developmental outcome than subjects with normal MRI and subjects with hippocampal injuries. Moreover, Alderliesten *et al.*\[[@ref15]\] showed that low apparent coefficient diffusion values and high lactate/NAA ratios of basal ganglia at ^1^HMRS were associated with a negative outcome at 24 months. No abnormalities of lactate were seen in our patients (none had advanced neuronal necrosis in the damaged areas because of the restricted temporal window between ischemic processes, cooling, and MRI), whereas area under the curve of NAA in basal ganglia represented a more useful prognostic index.

The lack of strong correlations between neurocognitive outcome and structural and diffusion abnormalities in cerebral structures other than basal ganglia partially agrees with previously reported data. Cheong *et al.*\[[@ref13]\] reported a relatively low negative predictive value (between 54% and 63%) for lesions involving posterior limbs of internal capsula, white matter, and cortical grey matter. Charon *et al.*\[[@ref6][@ref7]\] reported that apparent coefficient diffusion measurements in posterior white matter, semioval centers, and posterior limbs of internal capsula added little to simple visual analysis of MRI for prognostic evaluations. Mean diffusivity and its variations are probably more reliable as a short-term index for the measurement of therapeutic response to hypothermia than for the prediction of long-term neurocognitive development.\[[@ref3]\]

The limitations of our study include (a) its retrospective nature; (b) the limited number of patients in the analyzed sample; (c) the variable timing for performing MRI; (d) the semiquantitative tool that was used for the evaluation of severity of brain MRI lesions (Bednarek severity score allowed a systematic evaluation of all cerebral lesions but it has been previously used only in the original paper, that had a different design if compared with ours)\[[@ref3]\]; (e) the technical limitations (better results for the detection of subtle lesions could be obtained with high-field 3T-MRI or functional MRI studies); (f) the selection bias that resulted from the exclusion of cases who did not reach 24 months of follow-up at the moment of the retrospective analysis (the minimum age that was considered to evaluate the progression of GMDS-III scores).This criterion could have facilitated the selection of less-severe cases because of the exclusion of newborns who died after hypothermia and of the patients who were lost in follow-up.

C[onclusion]{.smallcaps} {#sec1-5}
========================

This study suggests that a normal MRI in early post-cooling phases is strongly associated with a favorable developmental outcome and confirms the negative prognostic value of basal ganglia lesions. Future trials should be focused on the definition of the optimal timing of MRI investigations in order to address the treatment protocols and the post-intensive care rehabilitation strategies.

Ethical policy and institutional review board statement {#sec2-1}
-------------------------------------------------------

The study was approved by the ethics committee of Sapienza Università di Roma and Umberto I-Policlinico di Roma.

Financial support and sponsorship {#sec2-2}
---------------------------------

Nil.

Conflicts of interest {#sec2-3}
---------------------

There are no conflicts of interest.
